8ZD Stock Overview
An investment holding company, engages in the research and development of pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Abbisko Cayman Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.81 |
| 52 Week High | HK$1.00 |
| 52 Week Low | HK$0.30 |
| Beta | 1.22 |
| 1 Month Change | 16.55% |
| 3 Month Change | 40.87% |
| 1 Year Change | 117.74% |
| 3 Year Change | 80.80% |
| 5 Year Change | n/a |
| Change since IPO | -34.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8ZD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.0% | 0.6% | 1.7% |
| 1Y | 117.7% | -12.2% | 12.8% |
Return vs Industry: 8ZD exceeded the German Biotechs industry which returned -13.8% over the past year.
Return vs Market: 8ZD exceeded the German Market which returned 13.4% over the past year.
Price Volatility
| 8ZD volatility | |
|---|---|
| 8ZD Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 8ZD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8ZD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 281 | Yao-Chang Xu | www.abbisko.com |
Abbisko Cayman Limited, an investment holding company, engages in the research and development of pharmaceutical products in the People’s Republic of China. The company develops Pimicotinib, which is in Phase III clinical trial for the treatment of tenosynovial giant cell tumor; Irpagratinib for the treatment of hepatocellular carcinoma; ABSK043 that is in Phase I clinical trial for the treatment of non-small cells lung cancer; and ABSK061 for the treatment of solid tumors. It also develops Fexagratinib, which is in Phase II clinical trial for the treatment of urothelial carcinoma; ABSK121, a small molecule FGFR inhibitor that targets both wild-type and mutations of FGFR1-3; ABSK112, an EGFR Exon20ins inhibitor with selectivity over wild-type EGFR and brain-penetration activity; Mavorixafor, an orally bioavailable CXCR4 modulator; and ABSK051, a small molecule CD73 inhibitor for the treatment of various tumor types, such as lung and pancreatic cancer.
Abbisko Cayman Limited Fundamentals Summary
| 8ZD fundamental statistics | |
|---|---|
| Market cap | €526.50m |
| Earnings (TTM) | €3.46m |
| Revenue (TTM) | €61.66m |
152.0x
P/E Ratio8.5x
P/S RatioIs 8ZD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8ZD income statement (TTM) | |
|---|---|
| Revenue | CN¥503.99m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥503.99m |
| Other Expenses | CN¥475.69m |
| Earnings | CN¥28.30m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.045 |
| Gross Margin | 100.00% |
| Net Profit Margin | 5.62% |
| Debt/Equity Ratio | 0% |
How did 8ZD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 22:01 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abbisko Cayman Limited is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| null null | China International Capital Corporation Limited |